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Abstract
Myristoylated alanine-rich C-kinase substrate (MARCKS), a prominent substrate for conventional and novel protein
kinase C (PKC) isoforms, is involved in the regulation of membrane^cytoskeletal interactions. Addition of [Q-32P]ATP to the
membrane fraction of digitonin-permeabilized C6 glioma cells resulted in phosphorylation and release of MARCKS,
indicating involvement of an active membrane-bound kinase. Pretreatment of cells with 2 WM 4L-12-O-tetradecanoyl-
phorbol-13-acetate (L-TPA) for 18 h downregulated conventional (PKCK) and novel (PKCN) isoforms of PKC by s 90% in
both membrane and soluble fractions, but did not inhibit the rate of ATP-dependent phosphorylation or release of
MARCKS, or decrease levels of membrane-bound PKCj or PKCW. MARCKS phosphorylation was inhibited by
staurosporine, bis-indolylmaleimide (a PKC-specific inhibitor), Go«6983 (inhibits all isoforms except PKCW), and a peptide
from the calmodulin-binding domain of MARCKS, but was unaffected by EGTA or Go«6976 (inhibits cPKCs and PKCW).
Peptide mapping indicated similar in vivo and in vitro phosphorylation at serine residue(s) known to be phosphorylated by
PKC. These findings support a novel mechanism by which MARCKS may be regulated by an atypical PKC isoform in
phorbol ester-downregulated cells. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Protein kinase C (PKC) is a family of closely re-
lated serine/threonine kinases involved in the trans-
duction of a variety of extracellular signals regulating
many cellular responses, including changes in mor-
phology, gene expression, proliferation and di¡eren-
tiation [1,2]. The conventional cPKC isoforms (K, LI,
LII and Q) exhibit a requirement for phospholipids,
Ca2, and diacylglycerols (or tumor-promoting phor-
bol esters, such as L-TPA). Novel nPKC isoforms (N,
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O, R/L, a) exhibit Ca2-independent activity, while
the physiological activators of the atypical aPKC
members (j and V/S) have not been established. An-
other recently discovered related kinase is PKCW,
which is activated by phospholipids and diacylglycer-
ols or L-TPA, but has a distinct kinase domain and
substrate selectivity [3]. Relatively little is known
about the speci¢c roles of PKC isoforms in various
physiological processes, although it is generally as-
sumed that these depend on isoform-speci¢c expres-
sion, subcellular localization, mechanism of activa-
tion, and substrate speci¢city.
The myristoylated alanine-rich C-kinase substrate
(MARCKS) has been studied extensively and was
originally identi¢ed as a protein (termed ‘80K’) tran-
siently phosphorylated upon treatment of cells with
L-TPA (for reviews see [4,5]). MARCKS appears to
be essential for normal brain development [6], and
has been implicated in such diverse functions as cell
migration [7], growth suppression [8], phagocytosis
[9], and phospholipid signalling [10^12]. The
MARCKS protein contains three conserved do-
mains: (1) an amino-terminal domain which includes
the consensus sequence for N-myristoylation; (2) an
alternatively spliced domain of unknown function;
and (3) a centrally located basic domain (e¡ector
domain) which interacts with membrane phospholip-
ids [13^15], calmodulin [16], and ¢lamentous actin
[17]. PKC phosphorylation of MARCKS within
this domain disrupts all of these interactions and is
thought to be key to regulation of membrane^cyto-
skeletal interactions, local calmodulin levels, or mem-
brane phospholipid domains [10] in response to ago-
nist stimulation. Recent work has indicated that
MARCKS is e⁄ciently phosphorylated in vitro by
cPKC and nPKC isoforms, but not by atypical iso-
forms, such as aPKCj [18,19] or aPKCV [20]. Re-
ports of phosphorylation of MARCKS by proline-
directed kinases [21] and PKCW [22] have also ap-
peared. However, which kinases phosphorylate
MARCKS in intact cells and the functional conse-
quences of phosphorylation largely remain to be es-
tablished.
Rat C6 glioma cells provide a good system to ex-
amine regulation of MARCKS phosphorylation and
cellular localization. MARCKS is abundant in this
cell line [23] and undergoes phosphorylation and par-
tial translocation to the cytosol when cPKC and
nPKC are activated by L-TPA treatment [24]. The
relationships between these events and the in£uence
of calmodulin [25] and actin [26] have been well char-
acterized. In the present study, we show that
MARCKS is phosphorylated and released from
membranes in digitonin permeabilized C6 cells,
even after downregulation of cPKC and nPKC iso-
forms. These results indicate the presence of an alter-
nate Ca2-independent mode of regulation of mem-
brane^cytoskeletal events, which may operate in
addition to the usual L-TPA-stimulated phosphoryl-
ation and translocation of MARCKS by cPKC and
nPKC isoforms.
2. Materials and methods
2.1. Materials
[9,10-3H]Myristic acid (16 Ci/mmol), carrier-free
[32P]orthophosphoric acid, [Q-32P]ATP (10 mCi/ml),
and En3Hance were purchased from DuPont-NEN
(Mandel Scienti¢c, Guelph, Ont., Canada). Triton
X-100 (Surfact-Amps) was from Pierce (Chromato-
graphic Specialties, Brockville, Ont., Canada). Stau-
rosporine, 4L-12-O-tetradecanoyl-phorbol-13-acetate
(L-TPA), dimethylsulfoxide, digitonin, Staphylococ-
cus aureus V8 protease, phosphoamino acid stand-
ards and protease inhibitors were from Sigma (St.
Louis, MO). Bis-indolylmaleimide I (bIM) and
Go«6983 were from Calbiochem-Novabiochem (La
Jolla, CA), while Go«6976 was from BIOMOL Re-
search Laboratories, (Plymouth Meeting, PA).
Equipment and reagents for sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblot analysis were from Bio-Rad (Mississau-
ga, Ont., Canada). ECL chemiluminescent Western
blotting kits were from Amersham (Oakville, Ont.,
Canada). A⁄nity puri¢ed rabbit polyclonal antibod-
ies against peptide sequences unique to PKCK, L, N
and O were from Gibco BRL (Life Technologies,
Burlington, Ont., Canada), while antibodies directed
against PKCj (sc-216) and PKCW (sc-639) were from
Santa Cruz Biotechnology (Santa Cruz, CA).
MARCKS peptides were synthesized in the Depart-
ment of Biochemistry, Queen’s University, Kingston,
Ont., Canada. All other reagents were obtained from
standard suppliers.
BBAMCR 14427 5-1-99
D.N. Douglas et al. / Biochimica et Biophysica Acta 1448 (1999) 439^449440
2.2. Cell culture and labeling
C6 glioma cells (CCL-107) were maintained in
150-cm2 £asks containing 45 ml of Dulbecco’s modi-
¢ed Eagle’s medium supplemented with 10% fetal
bovine serum (FBS). Unless otherwise speci¢ed,
7U105 cells were seeded into 35-mm dishes in this
medium and were grown 5 days at 37‡C in a humidi-
¢ed atmosphere containing 95% air and 5% CO2.
Myristoylated proteins were labeled by incubating
cells (18 h, 37‡C) with 50 WCi [3H]myristic acid/ml,
complexed to 10% FBS in fresh medium. Phospho-
rylated proteins were labeled in intact cells (de¢ned
here as ‘in vivo’ phosphorylation) by incubation with
20 WCi [32P]orthophosphate in 1 ml of phosphate-free
medium supplemented with 10% dialyzed FBS for 4
h at 37‡C. In some experiments, conventional and
novel PKC isoforms were downregulated by addition
of 2 WM L-TPA for 18 h. Endogenous PKCs were
activated by incubation for 15 min with 200 nM L-
TPA in 1 ml of Na-HEPES bu¡er (15 mM HEPES,
140 mM NaCl, 1.2 mM KH2PO4, 4.7 mM KCl, 1
mM MgCl2, 5.5 mM glucose, pH 7.4) prior to per-
meabilization. Parallel culture dishes received an
equivalent volume (0.1%, v/v) of dimethylsulfoxide.
2.3. Permeabilization and subcellular fractionation
After washing twice with 2 ml Na-HEPES bu¡er,
cells were permeabilized with 100 WM digitonin in
1 ml of K-HEPES bu¡er (15 mM HEPES, 115 mM
KCl, 1.2 mM KH2PO4, 1 mM MgCl2, 10 mM KF,
4 mM Na-PPi, 5.5 mM glucose, 1 WM leupeptin,
200 WM phenylmethylsulfonyl £uoride, pH 7.0) by
incubation on a rotary shaker (70 rpm) for 10 min
Fig. 1. Cellular distribution of MARCKS and other
[3H]myristoylated proteins in permeabilized glioma cells. Cells
labeled for 18 h with 50 WCi [3H]myristate/ml were washed and
sequentially incubated with 1 ml of K-HEPES bu¡er contain-
ing: 100 WM digitonin (C1), 1 WM free calcium (C2), and 1%
Triton X-100 (M). The remaining cytoskeleton fraction (S) was
scraped and sonicated in 1 ml of K-HEPES bu¡er. All fractions
were centrifuged, supernatants were precipitated with acetone,
and equivalent volumes of each fraction (corresponding to 30,
10, 35, and 25 Wg protein, respectively, to re£ect subcellular dis-
tribution) were fractionated by SDS-PAGE and visualized by
£uorography (10-day exposure).
Fig. 2. E¡ects of staurosporine and EGTA on ATP-stimulated
translocation of MARCKS from the membranes of control and
downregulated C6 glioma cells. (A) Control cells (CON) and
cells downregulated (DR) with 2 WM L-TPA for 18 h were
washed and sequentially extracted with 1 ml of K-HEPES
bu¡er containing: 100 WM digitonin ( þ 200 nM STS as indi-
cated) (C1), 0.6 mM ATP or 1 mM EGTA ( þ as indicated)
(C2), and 1% Triton X-100 (M). Heat-stable proteins from each
fraction were separated by 10% SDS-PAGE and subjected to
Western blot analysis using anti-MARCKS antiserum and ECL
detection as outlined in the text. (B) Immunoreactive MARCKS
was quanti¢ed by densitometry and expressed as amount re-
leased into C2 as a percentage of total in C2 plus M fractions
for both control (white bars) and downregulated (black bars)
cells. The data represent the mean þ S.E.M. for three independ-
ent experiments.
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at 25‡C [26]. This extract (C1) containing cytosolic
proteins was removed and the adherent permeabi-
lized cells were washed brie£y with K-HEPES bu¡er
lacking detergent and then incubated for 15 min
at 25‡C with 1 ml fresh K-HEPES bu¡er with
[Q-32P]ATP (40 WCi, 600 WM) (‘in vitro’ phosphoryl-
ation). This second extract (C2) was removed and the
remaining particulate fraction (M) was solubilized in
K-HEPES bu¡er (1 ml) containing 1% (v/v) Triton
X-100. In some cases, the Triton X-100 insoluble
material (S) was recovered by scraping and sonica-
tion in 1 ml of K-HEPES bu¡er. Overall, cellular
fractions contained 29 þ 1% (C1), 9 þ 2% (C2),
35 þ 4% (M), and 27 þ 2% (S) of total cell protein
(1.0 þ 0.1 mg/dish) as determined by the Pierce Micro
BCA method, and 2.5 þ 0.3% (C1), 1.8 þ 0.2% (C2),
92.2 þ 0.6% (M), and 3.5 þ 0.8% (S) of total radio-
activity from [3H]myristic acid labeling as determined
by liquid scintillation counting. A similar distribu-
tion of MARCKS in cytosol and membrane fractions
of C6 cells is obtained by centrifugal separation of
sonicated cell extracts [24].
2.4. SDS-PAGE and Western blotting
Radiolabeled MARCKS was enriched in cellular
fractions by heat treatment (80‡C for 10 min) and
soluble proteins were precipitated with 14% (w/v)
trichloroacetic acid (for 32P-labeled MARCKS) or
5 vols. of cold acetone (for [3H]myristate-labeled
MARCKS) [23]. Equivalent portions (by volume)
of each fraction were separated by SDS-PAGE [27]
and stained with Coomassie blue prior to £uorogra-
phy or autoradiography using pre£ashed Amersham
Hyper¢lm MP. For immunoblot analysis, proteins
from each fraction were acetone precipitated without
prior heat treatment, separated by SDS-PAGE and
transferred to nitrocellulose membranes (0.45 Wm).
Membranes were blocked with 5% skim milk powder
in TBS-Tween bu¡er (25 mM Tris-HCl, pH 7.5,
125 mM NaCl, 0.1% Tween 20) prior to incubation
(1 h, 25‡C) with anti-rat MARCKS C-terminal pep-
tide antisera [23] at 1:3000 dilution or anti-PKCK, L,
N, O, W and j antibodies diluted at 2 Wg/ml in TBS-
Tween bu¡er. Nitrocellulose membranes were then
washed four times with TBS-Tween bu¡er, incubated
for 1 h in a 1:10 000 dilution of the appropriate
secondary anti-IgG conjugated to horse radish per-
oxidase, and immunoreactive proteins were detected
using the ECL Western blotting kit. Bands corre-
sponding to immunoreactive or radiolabeled proteins
were scanned using an Apple OneScanner with Ofoto
Fig. 3. Downregulation of PKC isoforms in C6 glioma cells in
response to L-TPA. Control (CON) and L-TPA-downregulated
(DR) cells were sequentially extracted with 1 ml K-HEPES
bu¡er containing 100 WM digitonin (C1), then with 1% Triton
X-100 (M). Immunoblots of C1 and M fractions were carried
out as described in the text to show the relative levels of
cPKCK, nPKCN, PKCW, and aPKCj. PKCj corresponds to the
lower band in the bottom panel (see text).
Fig. 4. Time course of ATP stimulated MARCKS phosphoryla-
tion in permeabilized C6 glioma cells. Cytosol was removed
from control (^ a ^) and down-regulated (- - b - -) cells by ex-
traction with 1 ml of K-HEPES bu¡er containing 100 WM digi-
tonin for 10 min. The remaining membrane fraction was then
incubated with 1 ml of K-HEPES containing 20 WCi [Q-32P]ATP
(0.6 mM) and 1 mM EGTA for the times indicated. The C2
fraction was removed and heat-stable proteins were separated
by 10% SDS-PAGE and visualized by autoradiography. The in-
tensities of the 80-kDa phosphorylated MARCKS band were
measured by densitometry and the results expressed as the inte-
grated intensity in arbitrary scan units.
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software (Light Source, Greenbrae, CA) and ana-
lyzed using NIH Image version 1.49 software.
2.5. Peptide mapping and phosphoamino acid analysis
Phosphopeptide mapping by limited proteolysis
with Staphylococcus aureus V8 protease was carried
out using a previously described method [28]. Brie£y,
32P-labeled MARCKS, obtained either in vitro by
incubation of digitonin permeabilized cells with
[32P]ATP or in vivo following L-TPA treatment of
cells pre-labeled with [32P]Pi, was located on dried
gels by autoradiography. Gel pieces were then ex-
cised, rehydrated, and applied to a 15% acrylamide
gel in the presence of Staphylococcus aureus V8 pro-
tease in sample loading bu¡er and electrophoresis
was carried out at 100 V. When the tracking dye
reached the stacking gel/resolving gel interface, the
power was discontinued for 20 min to permit incu-
bation of the V8 protease with the 32P-labeled
MARCKS. Electrophoresis was continued at 200 V
until completion and the gel was dried and subjected
to autoradiography.
Phosphoaminoacid analysis was performed using
heat-stable MARCKS, phosphorylated as described
above. 32P-labeled MARCKS was identi¢ed by auto-
radiography and recovered from dried gels; proteins
were hydrolyzed in 6 M HCl at 110‡C for 2 h [29].
Following hydrolysis, HCl was removed under a
Fig. 5. E¡ects of protein kinase inhibitors on MARCKS phos-
phorylation in permeabilized C6 cells. Cells (125 000 per 2 cm2
well) were cultured 4 days and downregulated by 18 h treat-
ment with 2 WM L-TPA in fresh medium. Cells were permeabi-
lized with 100 WM digitonin in 0.5 ml of K-HEPES bu¡er, then
preincubated for 5 min with 300 Wl of K-HEPES containing
1 mM EGTA and the indicated concentrations of STS, bIM,
Go«6976, and Go«6983 prior to addition of 10 WCi [Q-32P]ATP
(0.1 mM) for 10 min. Top: heat-stable proteins from this frac-
tion (C2) were separated by SDS-PAGE and visualized by
autoradiography as described in the text. Bottom: phosphoryl-
ated MARCKS was measured by densitometry and expressed
relative to levels in the absence of inhibitor (mean þ S.D. of
three independent experiments).
Fig. 6. Inhibition of MARCKS phosphorylation in C6 cell
membranes by a calmodulin-binding domain MARCKS pep-
tide. Permeabilized membranes from control or down-regulated
cells were prepared and incubated 15 min with 20 WCi [Q-32P]-
ATP (0.6 mM) as described in the legend of Fig. 4, in the pres-
ence of 60 WM of each of the following synthetic peptides de-
rived from human MARCKS [37] : CaM (KKKKRFSFK-
KSFKL), residues 153^166 from the calmodulin-binding
domain; Post CaM (KNKKEAGEGGE), residues 173^183; Pre
CaM (SPKAEDGATPSPS), residues 135^147; and Splice
(SSPSKANGQENG), residues 26^37. Inset shows heat-stable
proteins from the resulting C2 and M fractions of control cells
separated by SDS-PAGE and visualized by autoradiography.
Phosphorylated MARCKS in the C2 fraction was quantitated
by densitometry and expressed relative to that from control
(white bars) and downregulated (black bars) cells that received
no peptide. The data represent the mean þ range for two inde-
pendent experiments.
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stream of nitrogen gas and the sample was dissolved
in 10 Wl electrode bu¡er (acetic acid/88% formic acid/
water, 78:25:897, v/v), mixed with authentic phos-
phoserine, phosphothreonine and phosphotyrosine
standards (16 Wg each) and electrophoresed on What-
man cellulose thin-layer plates at 1000 V for 2 h.
Standards were detected by ninhydrin staining and
radiolabeled amino acids were detected by autora-
diography.
3. Results
3.1. ATP stimulates solubilization of membrane
associated MARCKS in permeabilized
C6 glioma cells
We have recently optimized the permeabilization
of C6 glioma cells by digitonin based on the release
of cytosolic (lactate dehydrogenase) and retention of
plasma membrane (5P-nucleotidase) marker proteins,
respectively [26]. Under these conditions, at least
50% of [3H]myristoylated MARCKS remained asso-
ciated with the membrane fraction of unstimulated
glioma cells. As shown in Fig. 1, further incubation
of permeabilized, cytosol-depleted cells for 15 min
with digitonin-free K-HEPES bu¡er prior to Triton
X-100 extraction resulted in selective release of addi-
tional MARCKS from the membrane fraction (com-
pare the enrichment of labeled MARCKS in lane C2
relative to other myristoylated proteins). Further
washes with K-HEPES bu¡er did not extract addi-
tional membrane-bound MARCKS, suggesting that
MARCKS released into fraction C2 was not due to
equilibrium partitioning. No signi¢cant levels of
MARCKS were detected in the Triton-insoluble cy-
toskeletal fraction (S) either by myristate labeling
(Fig. 1) or by Western blotting (not shown).
Addition of ATP to permeabilized C6 cells signi¢-
cantly enhanced the release of immunoreactive
MARCKS from the membrane fraction, as shown
in Fig. 2A (left panel) for control cells. Densitometric
analysis of these results revealed that ATP increased
MARCKS in the C2 fraction by at least two-fold
(Fig. 2B), with a corresponding decrease in the re-
maining membrane fraction. Similar results were ob-
served for 3H-labeled MARCKS. The ATP-stimu-
lated release of MARCKS from membranes was
not signi¢cantly a¡ected by bu¡ers containing 1 WM
free calcium (not shown) or EGTA up to 5 mM,
indicating that calcium was not required. Inclusion
of staurosporine (STS) during digitonin permeabili-
zation inhibited the stimulatory e¡ect of ATP on
subsequent MARCKS release in C2 (Fig. 2). Surpris-
ingly, the basal and ATP-stimulated release of
MARCKS from permeabilized cell membrane frac-
tions was not a¡ected when cells were preincubated
overnight with 2 WM L-TPA (Fig. 2A, right panel),
conditions previously shown to downregulate con-
ventional and novel PKC isoforms in C6 cells [30,31].
To assess the extent of downregulation of PKC
isoforms in membrane fractions after permeabiliza-
tion and removal of the cytosolic (C1) fraction,
known C6 isoforms cPKCK, nPKCN, aPKCj and
nPKCW were analyzed by Western blot analysis
(Fig. 3). After 18 h exposure to 2 WM L-TPA, mem-
brane associated cPKCK and nPKCN were decreased
Fig. 7. Comparison of in vivo and in vitro phosphorylated
MARCKS by limited S. aureus V8 proteolytic digestion. 32P-la-
beled MARCKS was obtained from the membrane fractions of
digitonin permeabilized control (CON) or downregulated (DR)
cells incubated with [Q-32P]ATP as described in the legend to
Fig. 4 (in vitro labeled). For comparison, MARCKS was also
labeled in intact cells preincubated 4 h with 20 WCi/ml [32P]Pi
and treated with 200 nM L-TPA for 15 min prior to extraction
with bu¡er containing 1% Triton X-100 (in vivo labeled). In vi-
tro-labeled MARCKS from heat-stable C2 fractions and in
vivo-labeled MARCKS from total cell lysates were visualized
on dried gels by autoradiography, excised and rehydrated as de-
scribed in the text. The gel pieces were then mounted onto a
15% acrylamide gel in the presence of Staphylococcus aureus V8
protease in sample loading bu¡er and electrophoresed. The gels
were dried and phosphopeptides visualized by autoradiography
(results shown are representative of ¢ve independent experi-
ments).
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by 91 þ 4 and 97 þ 1%, respectively (mean þ S.E.M.
of three independent experiments). Similar results
were noted for cytosolic cPKCK and nPKCN (Fig.
3), while neither of these isoforms were detected in
the cytoskeletal fraction. As noted previously [30],
nPKCO is present at very low levels and was absent
altogether in downregulated cells (not shown), while
PKCa, reported to be present in C6 glioma [31], was
not detected in our study.
By contrast, the level of membrane aPKCj (iden-
ti¢ed as the lower 76-kDa band in the bottom panel
of Fig. 3) was una¡ected by the downregulating con-
ditions, although some decrease was noted in the
cytosol. The aPKCj antibody used also speci¢cally
detected a slower migrating protein, which does not
appear to be aPKCj on the basis of its: (1) higher
mass (80 kDa); (2) sensitivity to downregulation by
L-TPA (Fig. 3); and (3) complete translocation to the
membrane when cells were extracted in the presence
of Ca2 (not shown). We conclude this upper band is
likely a modi¢ed cPKC isoform that is known to be
detected by anti-aPKCj C-terminal peptide antibod-
ies in various cell types [32,33]. Like aPKCj, the level
of membrane PKCW was una¡ected by L-TPA while
cytosolic PKCW decreased by 89 þ 5% (mean and
range of two experiments). Thus, ATP-stimulated
release of soluble MARCKS from membranes in per-
meabilized C6 cells appears to be due to a mecha-
nism which: (1) does not involve calcium; (2) is in-
hibited by STS; and (3) remains intact following
downregulation of conventional and novel PKC iso-
forms by L-TPA.
3.2. ATP-dependent release of MARCKS from the
membrane fraction is accompanied by
MARCKS phosphorylation
To determine whether the ATP-dependent trans-
location of MARCKS from the membrane fraction
might be a consequence of its phosphorylation, per-
meabilized cytosol-depleted C6 cells were incubated
for up to 20 min with digitonin-free K-HEPES bu¡er
containing [Q-32P]ATP (Fig. 4). There was a time-de-
pendent increase in the amount of in vitro phos-
phorylated MARCKS released into the C2 fraction
of control cells, and this rate was not appreciably
decreased in cells downregulated by L-TPA treat-
ment. Less than 10% of the 32P-labeled MARCKS
remained associated with the membrane fraction at
all time points, suggesting that phosphorylation of
MARCKS results in its release from the membrane
under these conditions.
Protein kinase inhibitors were used to explore the
nature of the membrane-bound kinase responsible
for phosphorylation and translocation of MARCKS.
STS, an e¡ective but relatively non-speci¢c inhibitor
of PKC, completely inhibited in vitro phosphoryl-
ation of MARCKS in the C2 fraction of both con-
trol (not shown) and downregulated cells (Fig. 5).
bIM, a more selective PKC inhibitor also known as
Go«6850 and GF 109203X [34], also inhibited
MARCKS phosphorylation in downregulated cells,
although it was less e¡ective (IC50V50 nM) than
STS (IC50V5 nM). To further discriminate among
PKC isoforms, the PKC isoform-selective inhibitors
Go«6976 (reported to be e¡ective against cPKCs [35]
and PKCW [36]), and Go«6983 (inhibits all PKC iso-
forms except PKCW [36]) were also evaluated. As
shown in Fig. 5, Go«6983 did inhibit MARCKS phos-
phorylation with an IC50 in the 100-nM range, while
Go«6976, at concentrations below 1 WM, had little
e¡ect. In contrast, Go«6976 e¡ectively inhibited
L-TPA-stimulated in vivo phosphorylation of
MARCKS in C6 cells (not shown).
As MARCKS is known to be phosphorylated by
PKC on serine residues within the central calmodu-
lin-binding domain, we evaluated the ability of var-
ious peptides based on di¡erent regions of the human
MARCKS protein [37] to inhibit in vitro MARCKS
phosphorylation in membranes from permeabilized
cells (Fig. 6). Only the peptide from the calmodu-
lin-binding domain of MARCKS inhibited phos-
phorylation and translocation of MARCKS in both
control and downregulated cells. This peptide con-
tains two serine residues (corresponding to S152
and S156 of rat MARCKS [38]) phosphorylated by
PKC. In another experiment, inhibition of
MARCKS phosphorylation by the calmodulin-bind-
ing domain peptide was found to be dose-dependent
and complete at 200 WM peptide.
3.3. MARCKS phosphorylation occurs at the same
sites in intact and permeabilized C6 cells
Phosphoamino acid analysis was carried out with
MARCKS phosphorylated either in vitro, by incuba-
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tion of permeabilized cells (both control and down-
regulated) with [32P]ATP, or from [32P]Pi-prelabeled
cells stimulated with L-TPA. In all cases, MARCKS
was found to be phosphorylated on serine residues
only (data not shown). Limited proteolytic mapping
was used to further characterize MARCKS phos-
phorylation by the L-TPA-insensitive, Ca2-inde-
pendent, membrane-associated kinase. MARCKS
was labeled in vitro by incubation of membrane frac-
tions from control or downregulated cells with
[32P]ATP, then partially digested with S. aureus V8
protease and separated on a 15% acrylamide gel (Fig.
7). The labeled protein fragments observed (i.e. the
13-kDa fragment also noted in an earlier study [21])
were identical to those obtained from MARCKS
phosphorylated in vivo by L-TPA treatment of cells
prelabeled with [32P]Pi. Similar conclusions were ob-
tained when in vivo and in vitro phosphorylation
sites were compared by two-dimensional tryptic pep-
tide mapping (data not shown).
4. Discussion
The permeabilized C6 glioma cell system used in
the present investigation was initially developed to
examine the interactions of MARCKS under rela-
tively physiological conditions in which the environ-
ment could be carefully controlled. Speci¢cally, we
wished to establish the speci¢city of, and factors in-
£uencing, phosphorylation and release of membrane
bound MARCKS in vitro by exogenous PKC iso-
forms after removal of endogenous cellular PKC
(most of which is cytosolic in unstimulated cells).
These experiments led to the unexpected discovery
that MARCKS is continuously released in an ATP-
stimulated manner after permeabilization and cytosol
depletion, and that the membrane-bound kinase re-
sponsible is independent of Ca2 and not a¡ected by
phorbol ester-induced PKC downregulation. These
results suggest a novel method by which MARCKS
might regulate the cyclic attachment and detachment
of actin ¢laments to membranes that appears to
underlie the role of this protein in actin^cytoskeletal
interactions [5].
Recent evidence has indicated that attachment to
cellular membranes is through at least two distinct
sites on MARCKS: (1) by insertion of the N-termi-
nal myristoyl moiety directly into the lipid bilayer
[39]; and (2) by electrostatic attachment of an elon-
gated central basic domain with anionic phospholip-
ids [13]. Theoretical considerations suggest that
each of these interactions alone is insu⁄cient for
stable association of MARCKS with the membrane
and that both are required for this interaction
[14,40]. This is supported by the general observation
that non-myristoylated MARCKS interacts poorly
with lipid bilayers [41], and that phosphorylation
by PKC in the e¡ector domain results in transloca-
tion of MARCKS to the cytosol [42,43]. However, a
direct relationship between MARCKS phosphoryla-
tion and membrane interaction may be complicated
by other factors, such as phospholipid composition
[13,15], as well as actin and calmodulin binding [26].
These factors could underlie reports of uncoupling of
phosphorylation and translocation [24,41,44], and
partial membrane association of non-myristoylated
MARCKS under some conditions [41,45].
MARCKS is an excellent in vitro substrate for
cPKC and nPKC isoforms [18,19,46], and is also a
substrate of proline-directed kinases [21]. However,
several studies have shown that MARCKS is not
phosphorylated by atypical PKC isoforms [18^20],
although the calmodulin-binding domain peptide of
MARCKS is a good substrate for aPKCj in vitro.
Several pieces of information implicate a member of
the PKC family in the phosphorylation and release
of MARCKS observed in the present study. First,
phosphorylation and translocation of MARCKS
were inhibited by STS and speci¢c PKC inhibitors:
bIM I (an inhibitor of all PKC isoforms [34,35]) and
Go«6983 (inhibits all PKC isoforms except PKCW
[36]). Second, phosphorylation was speci¢cally inhib-
ited by a peptide from the calmodulin-binding do-
main of MARCKS, but not by other serine-contain-
ing MARCKS peptides. Third, phosphoamino acid
analysis and phosphopeptide mapping indicated that
phosphorylation occurs on serine residue(s) in the
calmodulin-binding domain both in intact cells and
membranes. This rules out phosphorylation by pro-
line-directed kinases, such as cdc2, which phospho-
rylate MARCKS (on both Ser and Thr) at di¡erent
sites [21].
It is unlikely that MARCKS phosphorylation in
permeabilized C6 cell membranes is due to cPKC
or nPKC isoforms. While both cPKCK [11,46] and
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nPKCN [47] have been implicated in MARCKS lo-
calization and function, overnight pretreatment of
cells with L-TPA depleted levels of cPKCK and
nPKCN in the membrane by s 90% (shown in Fig.
3 and previously [30,31]), yet did not have a substan-
tial e¡ect on either the rate or extent of MARCKS
phosphorylation. Similarly, PKCO (present at very
low levels) and PKCa (not detected in our experi-
ments), have been reported to be completely down-
regulated under similar conditions in C6 cells [31].
The possibility that residual cPKCK in the mem-
brane might be responsible for MARCKS phospho-
rylation is not consistent with the reported sensitivity
of human cPKCK to low nanomolar concentrations
of bIM, Go«6983, and Go«6976 [35,36], especially in
the case of the latter which had little e¡ect in vitro.
Phosphorylation and solubilization of MARCKS
was also not dependent on the presence of Ca2,
which would be required for cPKCK activity. Our
inhibitor experiments do not rule out involvement
of nPKCN, known to be inhibited by bIM I
(IC50 = 210 nM) and Go«6983 (IC50 = 10 nM), but
not Go«6976 [35,36]. However, the virtual absence
of immunoreactive membrane nPKCN after downreg-
ulation (3% of control) makes this highly improb-
able. Moreover, MARCKS phosphorylation was
not stimulated by addition of L-TPA to permeabi-
lized C6 cells under control or downregulating con-
ditions, suggesting that residual traces of a phorbol
ester-stimulated isoform (such as nPKCN) are not
involved.
The present study demonstrates that C6 glioma
cells contain PKCW, and its resistance to downregu-
lation by L-TPA in the membrane fraction makes
this unusual isoform a potential candidate for
MARCKS phosphorylation. Indeed, PKCW has re-
cently been shown to phosphorylate MARCKS and
its e¡ector domain peptide [22], although MARCKS
is a poor substrate for this isoform, likely due to the
absence of Leu at the 35 position relative to the
target Ser residue(s) [48]. However, the relative in
vitro sensitivity of PKCW to Go«6976 (IC50 = 20 nM)
and Go«6983 (IC50 = 20 WM) [36] is directly opposite
to what we observed for MARCKS phosphorylation.
Moreover, the reported ability of L-TPA to stimulate
PKCW [22] is not consistent with our results. Thus, of
PKC isoforms known to be present in C6 cells, the
best candidate for the observed phosphorylation of
MARCKS in the membrane appears to be aPKCj.
This isoform is clearly resistant to downregulation by
L-TPA in C6 cells, and its inhibitor pro¢les with
Go«6983 and Go«6976 are consistent with our data,
although aPKCj is reported to be more resistant to
bIM [35,36]. The progressive inhibition by bIM and
Go«6983 over a relatively wide concentration range
might indicate that more than one PKC isoform is
responsible for MARCKS phosphorylation, or that
the presence of other factors (such as actin) in per-
meabilized cells modulate inhibition. If PKCj is at
least partially responsible for this activity, it would
indicate that permeabilized glioma cells provide a
more suitable environment for MARCKS kinase ac-
tivity than in vitro assays which employ recombinant
PKCj and puri¢ed MARCKS [18,19].
To our knowledge, this is the ¢rst study to indicate
that MARCKS can be phosphorylated and released
from membranes in cells downregulated of typical
cPKC and nPKC isoforms. A cycle of MARCKS
phosphorylation^dephosphorylation appears to be
essential to its function: directed mutagenesis and
PKC inhibitors disrupt cycling of MARCKS be-
tween the plasma membrane and lysosomes in ¢bro-
blasts, presumably related to membrane^cytoskeletal
alterations involved in endosomal transport [49].
Rapid stimulation of MARCKS phosphorylation
upon agonist-induced diacylglycerol formation and
PKC activation suggests that MARCKS is poised
to dynamically respond to extracellular signals lead-
ing to membrane cytoskeletal rearrangement [5].
Clearly, the major mode of MARCKS regulation
in most cell types (including C6 glioma) is likely to
involve activation and translocation of cPKC and
nPKC isoforms followed by MARCKS phosphoryl-
ation and translocation. However, our observations
could be related to a necessity for a low (perhaps
constitutive?) level of MARCKS cycling to maintain
membrane plasticity in the absence of overt PKC
activation. Alternatively, they could reveal the pres-
ence of a parallel signalling pathway that converges
at MARCKS.
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